Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: MiMedx Group (MDXG), ProKidney (PROK) and Centessa Pharmaceuticals (CNTA)

Tipranks - Tipranks - Tue Jul 1, 2025

Analysts have been eager to weigh in on the Healthcare sector with new ratings on MiMedx Group (MDXG – Research Report), ProKidney (PROK – Research Report) and Centessa Pharmaceuticals (CNTA – Research Report).

Don’t Miss TipRanks’ Half-Year Sale

MiMedx Group (MDXG)

In a report released today, Chase Knickerbocker from Craig-Hallum maintained a Buy rating on MiMedx Group. The company’s shares closed last Friday at $5.94, close to its 52-week low of $5.47.

According to TipRanks.com, Knickerbocker is a 4-star analyst with an average return of 7.8% and a 51.2% success rate. Knickerbocker covers the Healthcare sector, focusing on stocks such as Phathom Pharmaceuticals, Xtant Medical Holdings, and Avadel Pharmaceuticals. ;'>

Currently, the analyst consensus on MiMedx Group is a Strong Buy with an average price target of $12.00, implying a 104.1% upside from current levels. In a report issued on June 18, Northland Securities also maintained a Buy rating on the stock with a $12.00 price target.

See today’s best-performing stocks on TipRanks >>

ProKidney (PROK)

In a report released today, Jason Gerberry from Bank of America Securities downgraded ProKidney to Sell. The company’s shares closed last Monday at $0.66.

According to TipRanks.com, Gerberry is a 4-star analyst with an average return of 2.6% and a 49.4% success rate. Gerberry covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Amphastar Pharmaceuticals, and Arrowhead Pharmaceuticals. ;'>

Currently, the analyst consensus on ProKidney is a Hold with an average price target of $3.00.

Centessa Pharmaceuticals (CNTA)

Centessa Pharmaceuticals received a Buy rating and a $35.00 price target from BMO Capital analyst Kostas Biliouris today. The company’s shares closed last Monday at $13.26.

According to TipRanks.com, Biliouris is ranked 0 out of 5 stars with an average return of -11.7% and a 33.2% success rate. Biliouris covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, Rocket Pharmaceuticals, and Crispr Therapeutics AG. ;'>

Currently, the analyst consensus on Centessa Pharmaceuticals is a Strong Buy with an average price target of $32.57, which is a 148.1% upside from current levels. In a report issued on June 17, TD Cowen also maintained a Buy rating on the stock.

Read More on MDXG:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).